Answers are grounded in this paper and cite their sources.
Follicular lymphoma (FL) usually requires multiple lines of therapy, and disease control remains largely insufficient with conventional chemoimmunotherapy. Several T-cell-redirecting strategies recently approved in the relapsed/refractory setting have the potential to improve outcomes and change the treatment algorithm in FL. This review focuses on the role of chimeric antigen receptor T cells and bispecific antibodies in FL, paying special attention to sequencing approaches and future directions.
No takes yet. Share an insight, caveat, or question.
Iacoboni et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: